歐康維視、基石藥業漲超10% 領漲港股生物醫藥B類股
格隆匯5月26日丨港股市場生物醫藥B類股普漲,其中,歐康維視生物和基石藥業漲超10%領漲板塊,基石藥業最近4個交易日累漲36%,股價創2年新高;歌禮制藥漲超9%,嘉和生物、中國抗體、永泰生物和康方生物等均明顯上漲。歐康維視此前公吿一款用於延緩或減慢兒童和青少年近視的滴眼液在英國的III期臨牀試驗許可獲受理。基石藥業5月22日在上海舉辦首屆腫瘤精準治療論壇,首席醫學官楊建新表示,腫瘤創新藥獲批速度之迅速超出了公司的預期。從基石藥業和國外籤合同到遞交新藥上市申請(NDA),再到批下來只用了不到3年的時間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.